Lubitz Andrea, Woo Karen
Department of Surgery, Division of Vascular and Endovascular Surgery, Lewis Katz School of Medicine at Temple University Hospital, Philadelphia, PA.
Department of Surgery, Division of Vascular Surgery, David Geffen School of Medicine at UCLA, 200 UCLA Medical Plaza, Suite 526, Los Angeles, CA 90077.
Semin Vasc Surg. 2024 Dec;37(4):369-374. doi: 10.1053/j.semvascsurg.2024.09.003. Epub 2024 Sep 30.
The most recent National Kidney Foundation Kidney Disease Outcomes Quality Initiative guidelines shifted emphasis to kidney replacement modality selection and vascular access planning and creation of the Endstage Kidney Disease Life-Plan, which promotes a patient-centered approach. The Life-Plan is intended to be created through discussions between the patient and their multidisciplinary care team to ultimately develop a lifelong kidney replacement therapy strategy. The focus of the Life-Plan is to engage the patient in a multidisciplinary patient-centered approach. The Life-Plan includes selection of the most suitable treatment modality (eg, hemodialysis, peritoneal dialysis, or transplantation), setting (home or center), and type of vascular access. Ultimately, this approach considers overall patient health, preferences, and anatomic factors. Patients choose between hemodialysis, which can be performed either in center or at home, and peritoneal dialysis. When considering vascular access, options consist of tunneled dialysis catheter, arteriovenous fistula, and arteriovenous graft. Each modality and vascular access type has benefits and disadvantages that should be weighed carefully with the patient and their supportive team to arrive at a decision that aligns as closely as possible with each individual patient's circumstances.
美国国家肾脏基金会最新的《肾脏病预后质量倡议》指南将重点转向肾脏替代治疗方式的选择、血管通路规划以及制定终末期肾病生命计划,该计划倡导以患者为中心的方法。生命计划旨在通过患者与其多学科护理团队之间的讨论来制定,最终制定出终身肾脏替代治疗策略。生命计划的重点是以多学科、以患者为中心的方法让患者参与进来。生命计划包括选择最合适的治疗方式(如血液透析、腹膜透析或移植)、治疗地点(家中或中心)以及血管通路类型。最终,这种方法会考虑患者的整体健康状况、偏好和解剖因素。患者在可在中心或家中进行的血液透析和腹膜透析之间做出选择。在考虑血管通路时,选择包括带隧道的透析导管、动静脉内瘘和动静脉移植物。每种治疗方式和血管通路类型都有其优缺点,应与患者及其支持团队仔细权衡,以做出尽可能符合每个患者具体情况的决定。